Top 5 Drug Type | Count |
---|---|
Small molecule drug | 4 |
Target |
Mechanism AChE activators [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date17 Jan 2002 |
Target |
Mechanism GABAA receptor agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date20 Dec 1985 |
Target |
Mechanism β2-adrenergic receptor agonists |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. Japan |
First Approval Date13 Jan 1973 |
Start Date29 Dec 2016 |
Sponsor / Collaborator |
Start Date01 Jul 2014 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Salbutamol sulfate ( β2-adrenergic receptor ) | Bronchial Spasm More | Approved |
Midazolam Hydrochloride ( GABAA receptor ) | Status Epilepticus More | Approved |
Atropine/Pralidoxime Chloride ( ACHE x mAChRs ) | Organophosphate Poisoning More | Approved |
Naloxone hydrochloride ( μ opioid receptor ) | Opiate Overdose More | Approved |
Sumatriptan Succinate ( 5-HT1B receptor x 5-HT1D receptor ) | Migraine Disorders More | Withdrawn |